DAPD Emory University/Triangle Pharmaceuticals/Abbott Laboratories

Current Opinion in Investigational Drugs

Volumn 2, Issue 3, 2001, Pages 348-353

  Corbett, A H ^a   Rublein, J C ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 3' AZIDO 2',3' DIDEOXY 5 METHYLCYTIDINE; ADENOSINE DEAMINASE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA D 2,6 DIAMINOPURINE DIOXOLANE; DIDANOSINE; DIOXOLANE GUANINE; DNA POLYMERASE; EMTRICITABINE; FAMCICLOVIR; LAMIVUDINE; NEVIRAPINE; PRODRUG; PROTEINASE INHIBITOR; PURINE NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CROSS RESISTANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TRANSFORMATION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; NONHUMAN; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXICITY TESTING; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIOXOLANES; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; FORECASTING; HEPATITIS B VIRUS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR STRUCTURE; PURINE NUCLEOSIDES;

EID: 0035062365     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. 1,3-Diozolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes
2. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (Marmota monax)
3. Triangle Pharmaceuticals licenses anti-AIDS compounds from Emory Univ.
4. ISAR pre-satellite symposium: Recent advances in the chemistry and pharmacology and antiviral agents
5. Pharmacokinetics of dioxolane guanine (DXG) following administration of DXG and prodrug, (-)-β-D-2,6-diaminopurine dioxalane (DAPD), to rats
6. Triangle Pharmaceuticals Inc-Form 10K
7. Anti-HIV activity in the HuPBMC SCID mouse model of six novel nucleoside analogs: (-)-emtricitabine, (+/-)-emtricitabine, D-DAPD, D-D4FC, CS-92 CS-87
8. International Society for Antiviral Research - 12th International Conference: Clinical Update on Antiviral Drugs, Jerusalem, Israel
9. Effectiveness of combination therapies against hepatitis B virus (HBV) replication in vitro
10. DAPD: A novel inhibitor of hepatitis B virus replication
11. Emerging coactive therapies for HIV and HBV diseases
12. BioChem Pharma's antiviral patent portfolio-company holds patents on FTC and DPAD
13. The 12th International Conference on Antiviral Research, 21-25 April 1999, Jerusalem, Israel
14. DADP: A novel nucleoside inhibitor of HIV-1 replication, is active against drug-resistant isolates of HIV-1 from patients failing standard nucleoside therapy
15. Triangle Pharmaceuticals reports of DAPD preclinical safety and antiviral activity against drug-resistant HIV strains - Data presented at 39th Annual ICAAC Meeting in San Francisco
16. Perspectives for the treatment of hepatitis B virus infections
17. Mechanisms of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants
18. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir
19. Annual Report 1999-Triangle Pharmaceuticals
20. Triangle Pharmaceuticals presents antiviral activity of DAPD in HIV-infected patients with multiple drug failure
21. Breaking the Silence: 13th International AIDS Congress (Part II), Durban, South Africa
22. Clinical HIV supression after short term monotherapy with DAPD
23. Triangle Pharmaceuticals and Abbott Laboratories report drug candidate DAPD decreases viral load in patients infected with resistant virus when added to failing drug regimens - DAPD may provide new salvage therapy
24. Drug Therapy in HIV Infection - Fifth International Congress Glasgow, UK
25. Pharmacokinetics of (-)-β-D-dioxolane guanine and prodrug (-)-β-D-2,6-diaminopurine dioxolane in rats and monkeys
26. Inhibitory activity of new nucleoside analogs on wild type and YMDD mutants of the hepadnavirus reverse transcriptase
27. Two novel antiviral agents, DAPD and L-FMAU, which are active against wild-type and lamivudine-resistant HBV
28. Study of in vitro anti-HIV-1 activities of (-)-β-D-1,3-dioxolane guanine and (-)-β-D-2,6-diaminopurine dioxolane
29. The nucleoside reverse transcriptase inhibitor DAPD is active against resistant HIV-1 isolates from patients failing standard nucleoside therapy
30. Short-term monotherapy of DAPD in HIV-infected patients
31. DAPD: A novel inhibitor of HIV and HBV replication is active against drug-resistant viruses
32. Anti-HIV activity and tolerability of DAPD, a novel dioxolane guanine RT inhibitor: Preliminary results of a phase I/II clinical trial
33. Anti-HIV activity of DAPD in treatment-naive and treatment-experienced subjects